Cell line · CVCL_7076
MB49
Cancer cell line, Mus musculus. Mouse bladder transitional cell carcinoma. 38 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. MB49. Cell lines, record CVCL_7076. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_7076
On this page
Cell line
As Cellosaurus gives it.
- Name
- MB49
- Accession
- CVCL_7076
- RRID
- RRID:CVCL_7076
- Synonyms
- MB-49
- Species
- Mus musculus (Mouse)
- Sex
- Male
- Age at sampling
- Adult
- Category
- Cancer cell line
- Diseases
- Mouse bladder transitional cell carcinoma (NCIt C25823)
- Derived from
- Urinary bladder (in situ)
- Entry created
- 2012-04-04
- Entry updated
- 2026-06-25
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers38
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeted Nanoparticles for PROTAC-Mediated JAK1/JAK2 Degradation for Bladder Cancer Treatment. | Int J Nanomedicine | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Isocyanate-Modified Melatplatin(IV) Enhances Antitumor Efficacy via TCF4/COL6A3-Mediated Extracellular Matrix Remodeling and cGAS-STING Pathway Activation in Bladder Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Enfortumab vedotin induces immunogenic cell death and shows enhanced preclinical antitumor activity when combined with a PD-1 inhibitor. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Biophysical reprogramming of immunosuppressive neutrophils by cold atmospheric plasma reinvigorates antitumor immunity. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Induced pluripotent stem cell-derived dendritic cells potentiate the efficacy of interleukin-12-expressing oncolytic HSV-1. | Mol Ther Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Engineered T cell membrane coated nanoparticles reverse thermo-resistance and reprogram tumor microenvironment to synergistically potentiate bladder cancer photothermal immunotherapy. | J Nanobiotechnology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinoma. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| scResponse: A Rank-Based Method for Identifying Cell States That Contribute to Immunotherapy Response by Single-Cell Data. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 38
See all 38 papersRelatives7
| Relation | Cell line | Accession | Problem | Source |
|---|---|---|---|---|
| Derived from it | EDITGENE MB49-Cas9 | CVCL_F5PA | Cell lines | |
| Derived from it | EDITGENE MB49-CopGFP | CVCL_F5Z1 | Cell lines | |
| Derived from it | EDITGENE MB49-FLUC | CVCL_F5RI | Cell lines | |
| Derived from it | HyCyte MB49 KO-mSmim1 | CVCL_F1RG | Cell lines | |
| Derived from it | HyCyte MB49-Luc | CVCL_E3HW | Cell lines | |
| Derived from it | MB49-I | CVCL_VL62 | Cell lines | |
| Derived from it | MB49luc | CVCL_E8D4 | Cell lines |
Cell banks8
| Cell bank | Catalog number | Status | Source |
|---|---|---|---|
| AddexBio | C0002004/5005 | Cellosaurus | |
| CLS | 305240 | CLS | |
| CancerTools | 153368 | CancerTools | |
| EDITGENE | EDC00105 | EDITGENE | |
| Hysigen | TCM-C794 | Hysigen | |
| Millipore | SCC148 | Millipore | |
| Ubigene | YC-C104 | Ubigene | |
| Ximbio | 153368 | Ximbio |
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_7076
GET https://conductscience.org/api/cell-lines/v1/CVCL_7076/papers?page=2